Program

43
1
1

Journal Year Published

1
2
14
5
16
4
1
1
1
1

Author

46
185
178
145
136
125
123
118
117
108
99
88
81
77
58
54
50
46
42
37

Category

26
23
20
4
2
1
1

Keyword

9
8
6
5
5
4
4
3
3
3
2
2
2
2
2
2
2
2
2
1

Journal

5
3
3
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1

NCATS Publications

Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients.


Stukova M, Hall M, Tsotsoros SD, Madigan JP, Farrell NP, Gottesman MM


J. Inorg. Biochem. , (149), 45-8, 2015.

Article Pubmed

Sample image from publication page

The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity.


Chang KE, Wei BR, Madigan JP, Hall M, Simpson RM, Zhuang Z, Gottesman MM


Mol. Cancer Ther. , (14), 90-100, 2015.

Article Pubmed

Sample image from publication page

Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes.


Hall M, Telma KA, Chang KE, Lee TD, Madigan JP, Lloyd JR, Goldlust IS, Hoeschele JD, Gottesman MM


Cancer Res. , (74), 3913-22, 2014.

Article Pubmed

Sample image from publication page

Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family.


Pouliot LM, Chen YC, Bai J, Guha R, Martin SE, Gottesman MM, Hall M


Cancer Res. , (72), 5945-55, 2012.

Article Pubmed

Sample image from publication page

Synthesis and structure-activity evaluation of isatin-β-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein.


Hall M, Brimacombe K, Varonka MS, Pluchino KM, Monda JK, Li J, Walsh MJ, Boxer MB, Warren TH, Fales HM, Gottesman MM


J. Med. Chem. , (54), 5878-89, 2011.

Article Pubmed

Sample image from publication page